Analyst Price Targets — BHVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 28, 2026 12:10 pm | Sumant Kulkarni | Canaccord Genuity | $21.00 | $16.11 | StreetInsider | Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN) |
| August 26, 2026 2:17 pm | Chris Raymond | Raymond James | $30.00 | $16.47 | StreetInsider | Biohaven Pharma (BHVN) PT Lowered to $30 at Raymond James |
| August 12, 2026 11:47 am | — | Morgan Stanley | $19.00 | $14.49 | TheFly | Biohaven price target raised to $19 from $18 at Morgan Stanley |
| June 29, 2026 10:10 am | — | Needham | $11.00 | $15.83 | StreetInsider | BofA Securities Downgrades Biohaven Pharma (BHVN) to Underperform |
| May 13, 2026 12:01 pm | Terence Flynn | Morgan Stanley | $18.00 | $8.93 | TheFly | Biohaven price target lowered to $18 from $21 at Morgan Stanley |
| March 4, 2026 11:41 am | Douglas Tsao | H.C. Wainwright | $10.00 | $10.39 | StreetInsider | Biohaven Pharma (BHVN) PT Lowered to $10 at H.C. Wainwright |
| March 3, 2026 7:43 pm | Marc Goodman | Leerink Partners | $15.00 | $10.67 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Biohaven Pharma (BHVN), lowers EPS estimates |
| February 5, 2026 9:18 pm | — | Goldman Sachs | $23.00 | $10.76 | TheFly | Biohaven initiated with a Buy at Goldman Sachs |
| January 21, 2026 10:09 am | — | RBC Capital | $22.00 | $12.68 | TheFly | Biohaven upgraded to Outperform from Sector Perform at RBC Capital |
| December 3, 2025 11:08 am | — | H.C. Wainwright | $11.00 | $8.83 | TheFly | Biohaven downgraded to Neutral from Buy at H.C. Wainwright |
Latest News for BHVN
BlackRock Inc. bought a new stake in shares of Biohaven Ltd. (NYSE: BHVN) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,210,585 shares of the company's stock, valued at approximately $196,574,000. BlackRock Inc. owned approximately 8.77% of
Its partner is South Korean peer SK Biopharmaceuticals. It also secured a victory in a lawsuit.
Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform with SK Biopharmaceuticals. BHVN-1300's phase 3 for Graves' disease is underway; BHV-1400's phase 3 for IgA nephropathy is set to start in H2 2026. Opakalim [BHV-7000] for refractory focal epilepsy is fully enrolled in phase 2/3, with topline data expected in H2 2026 and a $350M…
Biohaven secures a transformative $795M global licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, notably opakalim. This agreement immediately strengthens BHVN's cash position, reduces R&D costs, and extends the funding runway, addressing prior liquidity concerns. I am upgrading BHVN to Buy, citing promising degrader pipeline assets targeting large autoimmune markets and pivotal trial…
Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BHVN.
U.S. House Trading
No House trades found for BHVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.